Peptide Companion
Back to catalog
Peptide Companion
single
Sexual Health
Vial: 10 mg

PT-141 (10 mg Vial)

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) derived as an active metabolite of Melanotan II. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide enhances sexual desire by activating MC4R in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area. This educational protocol presents a once-daily subcutaneous approach with gradual titration using a practical dilution for clear insulin-syringe measurements.

Dose
0.5–2 mg per injection
Frequency
As needed, 2–3 times weekly max
Timing
1–2 hours before desired effect
Duration
On-demand use

Melanocortin receptor agonist. Research on sexual function. Effects last 6-12 hours.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–8500 mcg (0.5 mg)15 units (0.15 mL)
Weeks 9–121000 mcg (1.0 mg)30 units (0.30 mL)
Weeks 13–161500 mcg (1.5 mg)45 units (0.45 mL)
Supplies Needed
  • •Peptide Vials (PT-141, 10 mg each):
  • •Insulin Syringes (U-100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • ScienceDirect

    Bremelanotide: pharmacology, toxicology, and therapeutic overview (active metabolite of Melanotan II)

    View source

  • PMC (2022)

    Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review

    View source

  • ResearchGate (2022)

    Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials

    View source

  • Mayo Clinic

    Bremelanotide (subcutaneous route): side effects, dosage, and precautions

    View source

  • MedlinePlus

    Patient instructions for subcutaneous injections: site rotation and technique

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle, site, and no-aspiration guidance)

    View source

  • CDC

    Vaccine administration best practices: during the injection (technique diagram)

    View source

  • CDC

    Storage and handling of immunobiologics: cold-chain and lyophilized product guidance

    View source

  • PMC (2019)

    Bremelanotide: first approval (comprehensive drug profile including cardiovascular considerations)

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View source

  • Diamond LE et al., J Sex Med (2006)

    Double-blind, placebo-controlled evaluation of intranasal bremelanotide (PT-141) in men with erectile dysfunction

    View source

  • Diamond LE et al., J Sex Med (2006)

    An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)

    View source

  • Molinoff PB et al., Ann N Y Acad Sci (2003)

    PT-141: a melanocortin agonist for the treatment of sexual dysfunction (pharmacology and early clinical data)

    View source

  • Kingsberg SA et al., Obstet Gynecol (2019)

    Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT; SC vs IN development context)

    View source

Educational content adapted from peptidedosages.com. Not medical advice.